Evogene Ltd (NASDAQ:EVGN) Position Lessened by Delek Group Ltd.

Delek Group Ltd. reduced its stake in Evogene Ltd (NASDAQ:EVGN) by 3.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 211,144 shares of the biotechnology company’s stock after selling 6,680 shares during the quarter. Delek Group Ltd. owned 0.82% of Evogene worth $332,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of EVGN. Eidelman Virant Capital purchased a new stake in Evogene during the second quarter valued at about $102,000. ARK Investment Management LLC grew its position in Evogene by 13.7% during the first quarter. ARK Investment Management LLC now owns 286,748 shares of the biotechnology company’s stock valued at $525,000 after acquiring an additional 34,626 shares during the period. Finally, Meitav Dash Investments Ltd. grew its position in Evogene by 44.7% during the first quarter. Meitav Dash Investments Ltd. now owns 28,521 shares of the biotechnology company’s stock valued at $51,000 after acquiring an additional 8,804 shares during the period. Hedge funds and other institutional investors own 29.23% of the company’s stock.

Separately, ValuEngine raised Evogene from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.

Shares of NASDAQ EVGN opened at $1.63 on Friday. The company has a quick ratio of 10.14, a current ratio of 10.14 and a debt-to-equity ratio of 0.06. Evogene Ltd has a 1-year low of $1.34 and a 1-year high of $3.32. The business has a 50-day moving average of $1.57 and a 200-day moving average of $1.77.

Evogene (NASDAQ:EVGN) last released its quarterly earnings results on Wednesday, July 31st. The biotechnology company reported ($0.16) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.19 by ($0.35). Evogene had a negative return on equity of 37.62% and a negative net margin of 1,193.65%. The business had revenue of $0.19 million during the quarter.

About Evogene

Evogene Ltd., a biotechnology company, engages in developing various products for various life science markets through the use of computational predictive biology platform in the United States, Germany, and internationally. It discovers and develops products in various areas, including ag-chemicals, ag-biologicals, seed traits, integrated castor oil ag-solutions, and human microbiome-based therapeutics.

Read More: What is a management fee?

Institutional Ownership by Quarter for Evogene (NASDAQ:EVGN)

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.